Skip to main content
. 2022 Mar 30;11(7):1923. doi: 10.3390/jcm11071923

Figure 1.

Figure 1

Imetelstat increased the percentage of dead cells in the LSC population in a dose-dependent manner in six pediatric AML PDX lines developed from diagnostic specimens (except DF-2, which was generated from a sample procured at relapse). Error bars denote SE of the mean from 2 independent experiments in triplicates. * p < 0.05, ** p < 0.01 comparing imetelstat treated cells to mismatch-treated cells at corresponding concentrations.